Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Account Payables: 2016-2025

Historic Change in Account Payables for Summit Therapeutics (SMMT) over the last 8 years, with Sep 2025 value amounting to -$839,000.

  • Summit Therapeutics' Change in Account Payables fell 363.54% to -$839,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 10302.69%. This contributed to the annual value of $2.0 million for FY2024, which is 10.96% down from last year.
  • As of Q3 2025, Summit Therapeutics' Change in Account Payables stood at -$839,000, which was down 104.68% from $17.9 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Change in Account Payables peaked at $17.9 million during Q2 2025, and registered a low of -$3.5 million during Q2 2022.
  • Moreover, its 3-year median value for Change in Account Payables was $308,000 (2023), whereas its average is $2.0 million.
  • Within the past 5 years, the most significant YoY rise in Summit Therapeutics' Change in Account Payables was 1,102.60% (2024), while the steepest drop was 1,122.56% (2024).
  • Quarterly analysis of 5 years shows Summit Therapeutics' Change in Account Payables stood at -$1.4 million in 2021, then crashed by 73.68% to -$2.4 million in 2022, then spiked by 71.63% to -$672,000 in 2023, then skyrocketed by 327.53% to $1.5 million in 2024, then slumped by 363.54% to -$839,000 in 2025.
  • Its Change in Account Payables was -$839,000 in Q3 2025, compared to $17.9 million in Q2 2025 and $356,000 in Q1 2025.